contain
sar
coronaviru
scv
outbreak
accompani
rapid
character
new
pathogen
genom
sequenc
encourag
develop
antiscv
therapeut
use
short
interf
rna
sirna
inhibitor
pair
sirna
duplex
identifi
potent
scv
inhibitor
vitro
evalu
vivo
efficaci
safeti
rhesu
macaqu
sar
model
use
intranas
administr
clinic
viabl
deliveri
carrier
three
dose
regimen
observ
scvinduc
sarslik
symptom
measur
scv
rna
presenc
respiratori
tract
microscop
inspect
lung
histopatholog
immunohistochemistri
section
test
macaqu
consist
demonstr
sirnamedi
antiscv
activ
prophylact
therapeut
efficaci
result
relief
anim
scv
infectioninduc
fever
diminish
scv
upper
airway
lung
alveoli
milder
acut
diffus
alveoli
damag
dad
dosag
sirna
use
mgkg
show
sign
sirnainduc
toxic
result
support
clinic
investig
antisar
sirna
therapeut
agent
warrant
studi
also
illustr
capabl
sirna
enabl
massiv
reduct
develop
time
novel
target
therapeut
agent
detail
repres
exampl
largemamm
sirna
use
outbreak
sever
acut
respiratori
syndrom
sar
pose
urgent
need
understand
diseas
pathogenesi
biolog
caus
agent
identifi
sar
coronaviru
scv
sar
develop
high
fever
follow
sever
clinic
symptom
includ
acut
respiratori
distress
syndrom
ard
diffus
alveolar
damag
dad
autopsi
contain
sar
achiev
larg
tradit
quarantin
sanit
measur
sinc
sar
newli
emerg
diseas
first
coronavirusmedi
diseas
safe
effect
vaccin
avail
establish
anticoronaviru
therapeut
candid
vaccin
becam
possibl
caus
viru
identifi
effort
alreadi
advanc
monkey
model
clinic
test
span
mani
approach
attenu
modifi
vaccinia
viru
mva
recombin
parainfluenza
viru
inactiv
whole
viru
dna
vaccin
howev
rapid
advanc
requir
rigor
lengthi
studi
illustr
difficulti
use
vaccin
develop
offer
rapid
solut
new
emerg
infecti
diseas
treat
sar
patient
combin
exist
drug
develop
includ
ribavirin
antibiot
antiinflammatori
steroid
immun
stimul
approach
achiev
clinic
success
mani
ongo
effort
develop
sarsspecif
drug
screen
small
molecul
inhibitor
current
biolog
approach
clarifi
strength
weak
approach
base
ultim
success
rate
time
cost
incur
identif
scv
caus
pathogen
sar
critic
contain
patient
manag
achiev
mainli
demonstr
exposur
cynomolgu
macaqu
scv
result
similar
symptom
sar
patient
also
creat
first
anim
diseas
model
critic
understand
sar
pathogenesi
also
evalu
potenti
vaccin
novel
therapeut
follow
develop
sever
other
demonstr
protect
pegyl
interferonfrom
scv
infect
cynomolgu
macaqu
seen
sar
patient
give
proof
effect
model
recent
rhesu
macaqu
model
sar
establish
intranas
instil
scv
strain
show
mani
element
patholog
similar
sar
patient
cynomologu
macaqu
model
see
note
pathogenes
includ
elev
bodi
temperatur
low
appetit
acut
dad
clearli
visibl
day
postinfect
dpi
somewhat
wors
sever
thu
offer
ideal
model
evalu
therapeut
candid
inhibit
scv
specif
potenti
treatment
sar
search
develop
antivir
agent
directli
viral
genom
sequenc
led
thorough
investig
sirna
previous
screen
sirna
candid
target
element
throughout
entir
scv
genom
identifi
sever
activ
sirna
duplex
use
fatal
rhesu
monkey
kidney
cell
activ
sirna
sequenc
inhibit
scv
also
report
screen
hand
candid
open
read
frame
cell
cultur
either
synthet
sirna
plasmidexpress
shrna
translat
vitro
inhibit
efficaci
use
treat
clinic
respiratori
infect
depend
clinic
accept
effect
administr
pair
sirna
show
promin
prophylact
therapeut
activ
cell
cultur
studi
refer
evalu
vivo
first
mice
use
report
gene
assay
subsequ
use
clinic
accept
intranas
administr
recent
establish
rhesu
macaqu
sar
model
studi
reveal
strong
evid
sirna
duplex
potent
prophylact
therapeut
antisar
agent
lack
toxic
nonhuman
primat
model
result
support
grow
expect
sirna
fulfil
need
move
rapidli
gene
sequenc
select
inhibitori
agent
mani
previous
intract
therapeut
target
see
note
offer
repres
exampl
procedur
correspond
result
expect
reader
test
target
optim
protocol
accordingli
two
scvspecif
sirna
duplex
target
respect
scv
genom
spike
protein
code
region
design
base
scv
complet
genom
sequenc
deriv
strain
select
base
antisar
potenc
valid
cell
cultur
studi
alway
use
mixtur
equal
amount
pair
control
sirna
duplex
sicona
siconb
without
homolog
human
sar
genom
also
use
mixtur
siconab
anoth
pair
unrel
control
sirna
duplex
siconc
sicond
use
mixtur
mous
studi
siconcd
sirna
duplex
consist
two
complementari
rna
strand
dtdtoverhang
manufactur
qiagen
gaithersburg
md
ggaugaggaaggcaauuuadtdt
sicona
ccgcuggagagcaacugcadtdt
siconb
gcuaugaaacgauaugggcdtdt
siconc
gcugacccugaaguucaucdtdt
sicond
costsav
purpos
minim
handl
pathogen
scv
mous
first
use
screen
larg
number
sirna
recombin
scv
target
move
monkey
divid
balbc
mice
week
old
four
group
n
pciscluc
report
plasmid
construct
earlier
insert
dna
fragment
contain
target
sequenc
dna
cmvdriven
transcript
initi
site
luciferas
code
sequenc
two
carrier
solut
infasurf
tm
see
note
use
intratrach
deliveri
siconcd
pciscluc
plasmid
typic
exampl
studi
design
shown
tabl
see
note
inocul
scvneg
healthi
monkey
ml
nasal
instil
mimick
natur
rout
scv
infect
sar
patient
also
deliv
siconab
sirna
agent
ml
intranas
macaqu
scvchalleng
treat
siconab
observ
clinic
sign
daili
includ
bodi
temperatur
size
lymph
node
bodi
weight
cough
sneez
appetit
aggress
etc
includ
liver
enzymat
analysi
sarsspecif
antibodi
detect
detail
liver
enzymat
analysi
chose
alanin
aminotransferas
alt
lactic
acid
dehydrogenas
ldh
creatin
kinas
ck
aspart
aminotransferas
ast
dpi
scv
infect
anim
everi
test
group
level
increas
experi
routin
blood
examin
also
indic
mark
increas
hemoglobin
hgb
platelet
plt
scvinfect
macaqu
contradictori
anoth
report
macaqu
sar
model
report
sar
patient
detect
antiscv
igg
igm
standard
elisa
macaqu
necropsi
dpi
collect
lung
conduct
thorough
microscop
inspect
lung
histopatholog
collect
organ
need
appear
morpholog
inspect
compar
use
intern
organ
coeffici
group
base
wet
weight
organ
per
g
averag
bodi
weight
isol
total
cellular
rna
use
qiaamp
rna
isol
kit
qiagen
synthes
first
strand
cdna
use
rnase
h
revers
transcriptas
random
primer
invitrogen
accord
manufactur
protocol
forward
revers
primer
fluoresc
probe
use
pcr
famagctacgagcaccagacacccttcgaaatrma
respect
perform
realtim
pcr
use
sequenc
detect
system
abi
ct
pcr
triplic
perform
scv
reisol
use
swab
sampl
serial
passag
vero
cell
cultur
previous
describ
creat
epoxi
resinfil
lung
block
right
upper
right
middl
lobe
perform
routin
patholog
analysi
briefli
first
fix
tissu
formaldehyd
emb
resin
section
stain
h
e
silver
stain
subject
microscop
examin
sever
lung
damag
determin
base
observ
five
differ
section
lung
readout
three
independ
pathologist
blind
sampl
id
resinembed
tissu
section
dewax
rehydr
immunohistochemistri
analysi
follow
incub
tissu
section
hydrogen
peroxid
min
rins
pb
treat
normal
sera
humid
chamber
min
treat
dilut
primari
antibodi
follow
treatment
appropri
dilut
secondari
antibodi
substrat
stain
hematoxylin
counterstain
examin
slide
microscop
first
antibodi
convalesc
antisera
sar
patient
pumh
stsd
second
antibodi
biotinyl
goatantihuman
igg
abc
kit
identifi
cell
type
base
separ
stain
correspond
mab
use
method
describ
previous
scvinfect
cell
count
within
microscop
imag
everi
lung
tissu
section
independ
collect
three
readout
blind
sampl
id
averag
cell
count
four
lung
group
n
compar
analyz
data
use
student
ttest
luciferas
express
mous
lung
fig
mean
bodi
temperatur
fig
histopatholog
score
comparison
fig
scvinfect
cell
count
fig
statist
signific
consid
p
regress
analysi
conduct
base
averag
bodi
temperatur
group
day
point
fig
concern
remain
whether
macaqu
sar
model
good
clinic
relev
rhesu
macaqu
model
present
studi
use
highli
virul
scv
strain
simul
pathogenesi
process
sar
patient
clear
clinic
relev
model
found
paramet
studi
includ
elev
bodi
temperatur
lung
patholog
scv
antigen
detect
epitheli
origin
type
pneumocyt
type
ii
pneumocyt
macrophag
provid
strong
support
model
attribut
requir
evalu
antiscv
sirna
studi
dose
intranas
rout
scv
challeng
prophylact
concurr
earli
postexposur
treatment
within
period
dpi
three
differ
treatment
regimen
achiev
potent
suppress
scvinduc
sar
pathogenesi
detect
scv
rna
genom
rtpcr
reveal
oropharyng
swab
sampl
treat
group
posit
versu
sampl
control
group
posit
similarli
use
immunohistochemistri
detect
scvinfect
cell
count
significantli
decreas
lung
section
treat
group
along
reduc
viral
spread
substanti
reduct
sarslik
clinic
symptom
lung
histopatholog
comment
regard
mechan
sirna
action
scv
order
present
studi
design
investig
sirnamedi
antiscv
effect
upper
airway
deep
lung
scvexpos
macaqu
occur
earli
phase
viral
infect
diseas
progress
impact
earli
phase
scv
infect
first
exhibit
mucos
epitheli
cell
upper
respiratori
tract
expect
sinc
scv
administ
intranas
instil
sirna
dose
complet
within
first
day
antisar
efficaci
result
one
follow
three
possibl
mechan
protect
cell
success
scv
infect
degrad
scv
mrna
inhibit
viral
protein
synthesi
infect
cell
obstruct
scv
genom
replic
spread
uninfect
cell
singl
prophylact
dose
provid
protect
compar
therapeut
treatment
use
multipl
dose
similar
clinic
benefit
observ
treatment
regimen
cd
pe
indic
research
may
tri
improv
dosag
regimen
studi
earli
sirna
intervent
scv
exposur
result
longlast
inhibitori
effect
averag
bodi
temperatur
viral
infect
cell
count
lung
damag
day
consid
sarsspecif
neutral
antibodi
scvinfect
macaqu
detect
earli
dpi
specul
clinic
benefit
sirnamedi
antisar
activ
observ
studi
consequ
combin
activ
sirna
agent
neutral
antibodi
suggest
multipl
antivir
mechan
oper
also
see
note
interest
advantag
use
sirna
sar
releas
proinflammatori
cytokin
alveolar
macrophag
propos
play
promin
role
sar
pathogenesi
point
intervent
contrast
proinflammatori
cytokin
treatment
intranas
deliveri
sirna
offer
uniqu
compliment
highspecif
inhibit
target
scv
minim
induct
proinflammatori
cytokin
antivir
respons
may
help
avoid
exacerb
symptom
lung
damag
report
sirna
administr
mous
model
lung
deliveri
evalu
differ
formul
includ
cation
polym
lipid
complex
use
either
intraven
airway
administr
shown
effici
antirsv
antiinfluenza
effect
well
eg
see
chapter
select
potent
scvspecif
sirna
agent
two
sirna
duplex
target
scv
genom
spike
protein
code
region
respect
chosen
vivo
studi
follow
reason
target
sequenc
two
sirna
duplex
exhibit
homolog
strain
use
cell
cultur
studi
strain
use
macaqu
model
publish
scv
strain
repres
isol
differ
phase
scv
evolut
recent
defin
wide
geograph
distribut
around
world
fig
b
two
potent
inhibitor
reduc
scv
replic
cell
among
set
activ
sirna
duplex
select
sirna
duplex
target
entir
scv
genom
c
synerg
effect
antiscv
activ
observ
combin
appli
cell
cultur
studi
show
strongest
prophylact
therapeut
effect
fig
c
among
mani
combin
activ
sirna
duplex
target
sequenc
share
homolog
human
genom
avoid
potenti
nonspecif
knockdown
patient
endogen
gene
addit
pair
nonrel
sirna
duplex
sicona
siconb
homolog
either
human
genom
sar
genom
valid
cell
cultur
studi
show
rnai
activ
scv
inhibit
chosen
neg
control
macaqu
studi
carrierdeliveri
reagent
transittko
polyethyleneimin
pei
report
carrier
intranas
intratrach
intraven
deliveri
sirna
mous
model
treatment
influenza
viru
rsv
infect
howev
carrier
feasibl
clinic
use
pei
particular
induc
sever
lung
inflamm
either
intraven
intratrach
deliveri
mice
base
experi
literatur
test
solut
infasurf
solut
also
appli
anim
model
deliveri
dna
sirna
codeliveri
pciscluc
plasmid
solut
illustr
higher
level
report
gene
express
stronger
rnai
effect
infasurf
solut
fig
amount
nucleic
acid
observ
lung
damag
intratrach
deliveri
nucleic
acid
provid
safe
baselin
sirna
dose
respiratori
tract
larger
mammal
score
patholog
rhesu
macaqu
vari
degre
sever
lung
damag
score
microscop
inspect
tissu
section
adopt
sixgrad
score
system
fig
normal
lung
tissu
control
anim
without
scv
infect
almost
normal
slightli
broaden
alveolar
septa
spars
monocyt
infiltr
hemorrhag
septa
elast
fiber
alveolar
wall
distort
shown
silver
stain
alveolu
septa
broaden
increas
infiltr
inflammatori
cell
extens
exud
septa
broaden
shrink
alveoli
caus
pressur
restrict
fusion
thick
septa
obviou
septa
hemorrhag
ruptur
elast
fiber
alveolar
wall
slight
filtrat
alveolar
caviti
massiv
cell
filtrat
alveoli
shrink
sheet
septa
fusion
necrot
lesion
hemorrhag
septa
massiv
cell
filtrat
alveolar
caviti
featur
acut
dad
scvinfect
rhesu
macaqu
lung
scvinduc
dad
lower
airway
first
observ
sar
patient
diseas
day
scvinfect
macaqu
lung
start
develop
acut
histopatholog
immunohistochemistri
microscop
inspect
found
necropsi
lung
develop
acut
dad
variou
degre
sever
typic
featur
scv
infectioninduc
lung
dpi
broken
alveolar
wall
interstiti
edema
fig
b
hyalinemembran
format
along
alveoli
pneumocyt
desquam
fig
c
damag
alveolu
fill
hemorrhag
pneumocyt
nuclear
enlarg
promin
nucleolu
amphophil
granular
cytoplasm
fig
interstiti
infiltr
neutrophil
lymphocyt
macrophag
fig
within
damag
lung
tissu
one
also
identifi
viralinfect
pneumocyt
infiltr
neutrophil
lymphocyt
monocyt
characterist
lung
inflamm
character
use
keratin
fig
fig
immunohistochem
stain
data
shown
observ
similar
lung
damag
observ
human
patient
coupl
sar
macaqu
model
suppress
sarslik
symptom
sirna
effect
sirna
reduc
essenti
clinic
symptom
describ
show
signific
lower
show
alveolar
wall
collaps
acut
diffus
interstiti
injuri
interstiti
edema
arrow
indic
earli
stage
diseas
b
section
macaqu
show
hyalinemembran
format
indic
arrow
along
alveoli
pneumocyt
desquam
c
lung
section
stain
h
e
highpow
magnif
c
section
macaqu
show
damag
alveoli
fill
hemorrhag
inflammatori
cell
indic
arrow
pneumocyt
nuclear
enlarg
promin
nucleolu
amphophil
granular
cytoplasm
result
focal
giantcel
format
arrow
indic
section
macaqu
show
inflammatori
cell
includ
neutrophil
lymphocyt
macrophag
monocyt
present
damag
alveoli
e
ihc
stain
scvinfect
monkey
lung
section
keratinspecif
mab
indic
epithelium
origin
pneumocyt
point
arrow
f
ihc
stain
scvinfect
monkey
lung
section
mab
indic
microphag
infiltr
arrow
point
patholog
score
suppress
scvinduc
fever
one
obviou
easili
detect
sirna
effect
rhesu
macaqu
model
scvspecif
igg
titer
everi
blood
sampl
collect
variou
time
point
also
illustr
inhibitori
effect
treat
anim
fig
scvspecif
igg
level
ic
ns
group
detect
earli
dpi
cd
pe
group
interestingli
scv
specif
igg
pl
group
detect
dpi
suggest
differ
mechan
action
antisar
activ
meanwhil
scvspecif
igg
level
group
well
detect
level
dpi
inhibit
scv
replic
macaqu
respiratori
tract
sirna
addit
act
antivir
lung
sirna
show
strong
efficaci
upper
respiratori
tract
reveal
rtpcr
analysi
oropharyng
swab
sampl
dpi
fig
prophylact
effect
sirna
note
deliv
prior
scv
infect
pl
group
use
singl
dose
abl
achiev
compar
inhibitori
effect
cd
pe
group
prophylact
antiscv
activ
result
lower
bodi
temperatur
fig
b
milder
lung
damag
fig
less
viral
rna
detect
fig
lower
number
scvinfect
cell
lung
fig
comparison
cd
pe
treatment
group
prophylact
efficaci
could
combin
direct
degrad
viral
rna
preexist
intracellular
within
upper
airway
cell
viral
particl
enter
decreas
replic
spread
scv
particl
reach
deeper
lung
cellular
antivir
activ
induc
sirna
transfect
interferon
respons
